You're viewing a public preview of this transaction Sign up free to access full investor details, deal amounts & seller data
Sign Up Free Log In
Deal Overview

CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights (Divestiture, in 2016)

Transaction #77998
Investor
1
Sign up to view
Target Company
CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights
Medical Products · United States
Seller
1
Sign up to view
17.50 USD
Deal Value
04 May 2016
Announced
Target Company
Company Sector Entity Type Status State Country
CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights Medical Products Private Active — United States
Investors 1
InvestorInvestment TypeAmount% Holding
View 1 Investor
Sign up to access investor names, investment types, deal amounts and ownership percentages
Sign Up Free Log In
Sellers 1
Seller
View 1 Seller
Sign up free to access seller names and full exit details for this transaction
Sign Up Free Log In
Frequently Asked Questions
What is the CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights acquisition deal?
This transaction is an acquisition of CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights (Divestiture) in 2016. The target company operates in the Medical Products sector. Full deal details are available on AcquityData.
When did the CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights acquisition happen?
This transaction was announced on 04 May 2016.
What is the deal value of the CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights acquisition?
The deal value for this transaction is 17.50 USD.
Who are the investors in the CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights transaction?
This transaction has 1 investor. Sign up to AcquityData to view investor names, investment types, amounts and ownership details.

Access the full CorMatrix Cardiovascular, Inc. - Synthetic Royalty and Milestone Rights deal profile

Unlock investor names, amounts, seller details and complete M&A intelligence in one connected platform.

Start Free Trial